抗体

抗人类p53, 无叠氮物

MBS335139

0.2毫克

310美元

单克隆

小鼠

未共轭

[B-F34]

酶联免疫吸附测定, 酶免疫法

抗体

抗人类p53, 无叠氮物

[p53]

[p53]

[P53; Cellular tumor antigen p53; cellular tumor antigen p53; tumor protein p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53]

[p53]

[TP53;TP53;P53;BCC7;LFS1;TRP53;P53]

P53_HUMAN

单克隆

Mouse IgG2b Kappa light chain

[B-F34]

小鼠

人类

393

Recognises wild type and mutant p53, the epitope is within residues 18-30 of human p53

离子交换层析

Phosphate-buffered saline. Sterile-filtered through 0.22 um. Carrier and preservative free

Store at +2-8 degree C for 12 months. For longer storage, freeze aliquots.

酶联免疫吸附测定(EIA)

Hybridoma: Myeloma X63/AG.8653 x Balb/c spleen cells. Immunisation: Recombinant p53 protein

23491729

BAC16799.1

P04637

24,401 Da

AMPK Signaling Pathway (198868); Activation Of BH3-only Proteins Pathway (1270270); Activation Of NOXA And Translocation To Mitochondria Pathway (1270272); Activation Of PUMA And Translocation To Mitochondria Pathway (1270273); Alzheimers Disease Pathway (672448); Amyotrophic Lateral Sclerosis (ALS) Pathway (920975); Amyotrophic Lateral Sclerosis (ALS) Pathway (83099); Amyotrophic Lateral Sclerosis (ALS) Pathway (511); Apoptosis Pathway (198797); Apoptosis Pathway (83060)

This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]

p53: a transcription factor and major tumor suppressor that plays a major role in regulating cellular responses to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis. More than 50 percent of human tumors contain a mutation or deletion of the TP53 gene. p53 is modified post-translationally at multiple sites. DNA damage induces phosphorylation of p53 at S15, S20 and S37, reducing its interaction with the oncoprotein MDM2. MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation. Phosphorylated by many kinases including Chk2 and Chk1 at S20, enhancing its tetramerization, stability and activity. The phosphorylation by CAK at S392 is increased in human tumors and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53. Phosphorylation of p53 at S46 regulates the ability of p53 to induce apoptosis. The acetylation of p53 appears to play a positive role in the accumulation of p53 during the stress response. Following DNA damage, p53 becomes acetylated at K382, enhancing its binding to DNA. Deacetylation of p53 can occur through interaction with SIRT1, a deacetylase that may be involved in cellular aging and the DNA damage response. p53 regulates the transcription of a set of genes encoding endosomal proteins that regulate endosomal functions. These include STEAP3 and CHMP4C, which enhance exosome production, and CAV1 and CHMP4C, which produce a more rapid endosomal clearance of the EGFR from the plasma membrane. DNA damage regulates a p53-mediated secretory pathway, increasing the secretion of some proteins such as Hsp90, SERPINE1, SERPINB5, NKEF-A, and CyPA, and inhibiting the secretion of others including CTSL and IGFBP-2. Two alternatively spliced human isoforms have been reported. Isoform 2 is expressed in quiescent lymphocytes. Seems to be non-functional. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. Protein type: Tumor suppressor; Motility/polarity/chemotaxis; Nuclear receptor co-regulator; Activator; Transcription factor; DNA-binding. Chromosomal Location of Human Ortholog: 17p13.1. Cellular Component: transcription factor TFIID complex; PML body; nuclear matrix; protein complex; mitochondrion; endoplasmic reticulum; replication fork; cytosol; nucleoplasm; nuclear body; mitochondrial matrix; nuclear chromatin; cytoplasm; nucleolus; chromatin; nucleus. Molecular Function: identical protein binding; protease binding; protein phosphatase 2A binding; zinc ion binding; p53 binding; protein N-terminus binding; receptor tyrosine kinase binding; protein phosphatase binding; protein kinase binding; transcription factor binding; histone acetyltransferase binding; protein binding; copper ion binding; histone deacetylase regulator activity; enzyme binding; DNA binding; protein heterodimerization activity; ubiquitin protein ligase binding; chaperone binding; damaged DNA binding; chromatin binding; transcription factor activity; ATP binding. Biological Process: viral reproduction; positive regulation of apoptosis; multicellular organismal development; positive regulation of transcription, DNA-dependent; T cell differentiation in the thymus; gastrulation; determination of adult life span; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to antibiotic; regulation of apoptosis; cellular response to glucose starvation; protein localization; negative regulation of neuroblast proliferation; base-excision repair; transforming growth factor beta receptor signaling pathway; cerebellum development; protein complex assembly; cell cycle arrest; ER overload response; response to X-ray; somitogenesis; release of cytochrome c from mitochondria; cell aging; chromatin assembly; circadian behavior; rRNA transcription; positive regulation of peptidyl-tyrosine phosphorylation; negative regulation of fibroblast proliferation; negative regulation of DNA replication; embryonic organ development; positive regulation of transcription from RNA polymerase II promoter; regulation of mitochondrial membrane permeability; negative regulation of transcription, DNA-dependent; regulation of tissue remodeling; negative regulation of apoptosis; transcription from RNA polymerase II promoter; G1 DNA damage checkpoint; DNA damage response, signal transduction by p53 class mediator; apoptosis; negative regulation of transcription from RNA polymerase II promoter; response to salt stress; entrainment of circadian clock by photoperiod; positive regulation of protein oligomerization; negative regulation of cell proliferation; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; positive regulation of histone deacetylation; regulation of transcription, DNA-dependent; T cell proliferation during immune response; double-strand break repair; positive regulation of neuron apoptosis; response to gamma radiation; cell differentiation; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; protein tetramerization; mitochondrial DNA repair; Notch signaling pathway; in utero embryonic development; B cell lineage commitment; multicellular organism growth; cell proliferation; T cell lineage commitment; neuron apoptosis; negative regulation of helicase activity; nucleotide-excision repair; protein import into nucleus, translocation; DNA strand renaturation; Ras protein signal transduction; negative regulation of cell growth; negative regulation of transforming growth factor beta receptor signaling pathway; blood coagulation; response to DNA damage stimulus. Disease: Papilloma Of Choroid Plexus; Pancreatic Cancer; Nasopharyngeal Carcinoma; Breast Cancer; Li-fraumeni Syndrome 1; Osteogenic Sarcoma; Colorectal Cancer; Glioma Susceptibility 1; Adrenocortical Carcinoma, Hereditary; Basal Cell Carcinoma, Susceptibility To, 7; Hepatocellular Carcinoma

0.2毫克

310美元